Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2

Chantal Mathieu, Paresh Dandona, Andreas L. Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus Florian Scheerer, Fredrik Thoren, Moshe Phillip

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2'. Together they form a unique fingerprint.

Medicine & Life Sciences